Ellen K. Ritchie

Hematology | Oncology

520 E 70th St # 3
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.

Journal: Blood advances

Published: November 06, 2025

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

Journal: Blood advances

Published: November 06, 2025

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Journal: NEJM evidence

Published: August 26, 2025

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis.

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis.

Journal: EJHaem

Published: May 20, 2024

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).

Journal: Transplantation and cellular therapy

Published: May 14, 2024

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.

Journal: The New England journal of medicine

Published: February 21, 2024

Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML.

Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML.

Journal: Leukemia & lymphoma

Published: April 05, 2023

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.

Journal: Haematologica

Published: November 11, 2022

Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.

Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.

Journal: Leukemia & lymphoma

Published: October 25, 2022

Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.

Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.

Journal: Leukemia & lymphoma

Published: October 07, 2022

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 18, 2022

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

Journal: Investigational new drugs

Published: March 28, 2022

Showing 1-12 of 77

Last Updated: 09/26/2026